Dernières nouvelles pour OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics

OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.

OrthoPediatrics Corp

<p><strong>Bruker Corporation&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) recently announced the acquisition of Dynamic Biosensors GmbH, or DBS, a pioneering company known for its development in biosensors. The acquisition is aimed at boosting Bruker&#39;s biophysical portfolio, which is used for analyzing molecular interactions and kinetics. Financial details of the transaction were not disclosed.</p>
<p>Hence, the latest strategic acquisition is expected to strengthen Bruker&#39;s position in the pharma and biotech industries. The acquisition will leverage Bruker&#39;s leading high-throughput Surface Plasmon Resonance (&quot;SPR&quot;) portfolio and Dynamic Biosensors&#39; unique instruments.</p>
<h2>BRKR&#39;s Likely Stock Trend Following the News</h2>
<p>Subsequent to the news, the share price of BRKR moved north 1% to $67.46 on Wednesday. The company is gaining a high level of synergies from its continuous effort to reinforce its leading position within the pharma and biotech industries. Given the latest acquisition announcement, we expect market sentiment toward BRKR stock to continue to remain positive.</p>
<p>BRKR currently has a market capitalization of $9.97 billion. The company has a trailing four-quarter average earnings surprise of 10.09%.</p>
<h2>Significance of Bruker&#39;s Latest Acquisition</h2>
<p>DBS develops and markets innovative technologies for studying complex molecular interactions and kinetics to support drug discovery in the pharma and biotech industries, as well as in basic and medical research. The new Dynamic Biosensor heliX&nbsp;instrument performs single-cell Interaction Cytometry (scIC) for kinetic measurements directly on cells, retaining the molecules&#39; native membrane environment. Bruker&#39;s SPR portfolio includes all new SPR #64 &lsquo;Triceratops&#39;, and the 24 and 32-spot Sierra-Pro SPR systems.</p>
<p>The Bruker SPR portfolio is a great match for DBS&#39;s products. Hence, following the acquisition, the combined Bruker Biosensors business will offer one of the most innovative ranges of instruments, workflows, and consumables for studying intermolecular and molecule-cell interactions in the drug discovery pipeline. The acquisition should help Bruker establish itself as a new technology leader in biosensors with a differentiated offering.</p>
<p>In fiscal 2025, Bruker expects its Biosensors business to have an additional revenue gain of more than $5 million from the DBS acquisition, with no material EPS impact.</p>
<h2>Other Recent Developments by Bruker</h2>
<p>In August, Bruker completed the installation and acceptance of a 1.2 GHz Avance NMR spectrometer at the Korea Basic Science Institute (&quot;KBSI&quot;). As the first 1.2 GHz NMR system in the Asia-Pacific region, it sets a new benchmark for molecular, cell biology and disease research using ultra-high-field NMR.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a8/80555.jpg?v=1793157732" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>The same month, the company announced a strategic investment in&nbsp;NovAliX &mdash; a preclinical Contract Research Organization specializing in expert drug discovery services. Bruker&#39;s partnership with NovAliX should enable both companies to accelerate the development, incubation, deployment and support of advanced biophysical methods. The collaboration will leverage Bruker&#39;s leading post-genomic solutions competencies, combined with NovAliX&#39;s expert services and innovation.</p>
<h2>Industry Prospects Favor Bruker</h2>
<p>Per a Grand View Research report, the global biosensors market was valued at $28.9 billion in 2023 and is expected to witness a compound annual growth rate of 8.0% from 2024 to 2030. The demand for biosensors is increasing due to the diversity of medical applications, the increasing number of diabetic patients, the high demand for compact diagnostic devices and rapid technological improvement.</p>
<h2>BRKR&#39;s Price Performance</h2>
<p>In the past year, BRKR&#39;s shares have risen 6% compared with the industry&#39;s 23.8% growth.&nbsp;</p>
<h2>BRKR&#39;s Zacks Rank and Key Picks</h2>
<p>BRKR currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the broader medical space are <strong>TransMedics Group</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), <strong>AxoGen</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and <strong>OrthoPediatrics</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>). While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 0.8% to $1.22 in the past 30 days. Shares of the company have soared 189.3% in the past year compared with the industry&#39;s 20.7% growth. TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 212.1% in the past year compared with the industry&#39;s 20.7% growth. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.</p>
<p>Estimates for OrthoPediatrics&#39; 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 5.8% against the industry&#39;s 20.7% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.</p>
<p><a href="https://www.zacks.com/stock/news/2347087/bruker-stock-gains-from-its-latest-acquisition-of-dynamic-biosensors?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347087">To read this article on Zacks.com click here.</a></p>


Earnings

Earnings Beats

Large Cap

Mid Cap

News

Offerings

Small Cap

Events

Markets

Analyst Ratings

Trading Ideas

AXGN

BRKR

KIDS

TMDX

Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

<p><strong>Hologic </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) has been gaining from new strategic product launches across Diagnostics and Breast Health. However, macroeconomic issues and unfavorable FX headwinds continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently.</p>
<h2>Major Factors Driving HOLX Stock Growth</h2>
<p>Among Hologic&#39;s advanced diagnostic products, primary revenue-generating ones are molecular diagnostic assays, which run on advanced instrumentation systems (Panther, Panther Fusion and Tigris), ThinPrep cytology system and the Rapid Fetal Fibronectin Test. With solid 10.5% growth, excluding COVID-19 sales in the fiscal third quarter of 2024, the Molecular Diagnostics business has consistently maintained high-single to double-digit gains in 13 of the last 15 quarters. Growth continues to be driven by the ongoing adoption and utilization of the broad menu in the Panther platform.</p>
<p>In Breast Health, Hologic expanded its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery. The business is thriving primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment, with key profitable offerings such as 3D digital mammography systems, image analytics software utilizing artificial intelligence, ultrasound imaging and minimally invasive breast biopsy guidance systems. In the third quarter of fiscal 2024, revenues increased 7.1% (excluding the divested SSI business), driven by domestic and international growth of 7.2% and 12.1%, respectively.</p>
<p>The company&#39;s international sales have been a major catalyst in the past few years, growing 5.1% year over year in the third quarter of fiscal 2024. Molecular STI testing, cytology and MyoSure experienced strong growth in the global markets. However, the company perceives it as still in the early phase of utilizing its expanded Panther installed base. Similarly, while international cytology and STI testing have more dominant U.S. revenues, they are expected to become meaningful revenue drivers in the international markets with time.</p>
<p>In order to streamline its operations and reduce the cost of revenues, Hologic has adopted a few significant strategies over the past few years. The company has invested deliberately and opportunistically in commercial areas where management has recognized a good return. These include Hologic&#39;s Genius marketing campaign in Breast Health, cervical cancer co-testing initiatives in Diagnostics, along with efforts to gain competitive market share with NovaSure.</p>
<div class="chart_embed">
<h2>Hologic, Inc. Price</h2>
<p><img alt="Hologic, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/2d/1727441408.png" style="height:251px; width:538px" title="" /></p>
<p><span style="font-size:13px">Hologic, Inc. price</span><span style="font-size:13px"> | Hologic, Inc. Quote</span></p>
<p>Per management, these strategic initiatives are already paying off through increased brand awareness, market share gains, and price stability, all of which will contribute to the company&#39;s higher sales. In the third quarter of fiscal 2024, the company was awarded the Innovative Technology Contract by Vizient, which expands access to its Surgical product lineup. The contract recognized Hologic&#39;s CoolSeal advanced energy portfolio and JustRight 5 mm stapler for their potential to enhance clinical care, patient safety and healthcare worker safety or improve business operations of healthcare organizations.</p>
</div>
<p>The stock has gained 12.2% year to date, compared with the industry&#39;s 7.6% rise. With the company currently focusing on the expansion of diagnostics assay and breast health offerings in global markets, we expect the stock to continue its upward movement in the coming days.</p>
<h2>Major Downsides for HOLX</h2>
<p>Continued concerns about the systemic impact of potential long-term and widespread recession have added to market volatility and diminished expectations for economic growth. The effect of the worldwide political and social uncertainty, including the impact on trade regulations and tariffs, economic disruptions as well as the ongoing supply chain constraints, have reportedly hampered the costs and sales of Hologic&#39;s products in certain countries in recent times. In the third quarter of fiscal 2024, Hologic&#39;s cost of revenues (product, service and other) rose about 1.9% year over year, while selling, general and administration expenses increased 4.2%.</p>
<p>These uncertainties surrounding global economic conditions and financial markets may cause medical equipment purchasers to decrease their medical health insurance premiums and procurement activities. Additionally, higher unemployment rates and health insurance premiums, co-payments and deductibles may result in cost-conscious consumers making fewer trips to their physicians and specialists, affecting the demand for the company&#39;s products and procedures.</p>
<p>We remain worried about the significant challenges Hologic faces owing to unfavorable foreign currency impact that has been adversely impacting the company&#39;s overall performance in the past few quarters. The company&#39;s international sales are often denominated in foreign currencies, including the euro, UK pound and renminbi. Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may reduce the reported value of Hologic&#39;s revenues outside the United States and associated cash flows. The company expects about $3 million adverse currency impact in the fourth quarter.</p>
<p>For several quarters in a row, declining COVID-19 assay revenues have been a headwind to some of the company&#39;s key performance metrics. Although the company returned to growth in the fiscal third quarter, the potential impact of the COVID-19 sales downturn still lingers.</p>
<p>Hologic&#39;s fiscal 2024 guidance assumes $70 million from COVID-19 assay sales, including $7 million in the fourth quarter of fiscal 2024. Overall, revenues from COVID-19-related items are expected to be approximately $105 million in fiscal 2024.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), <strong>AxoGen </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and <strong>OrthoPediatrics </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>). While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 156.5% in the past year compared with the industry&#39;s 17.5% growth. TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year, compared with the industry&#39;s 17.6% growth. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.</p>
<p>Estimates for OrthoPediatrics&#39; 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 17.1% against the industry&#39;s 20.8% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.</p>
<p><a href="https://www.zacks.com/stock/news/2342713/holx-stock-gains-from-new-offerings-despite-macro-issues?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2342713">To read this article on Zacks.com click here.</a></p>


Biotech

Government

Regulations

Guidance

Health Care

Contracts

Management

General

HOLX

HOLX Stock Gains From New Offerings Despite Macro Issues

<p><strong>OrthoPediatrics Corp.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>) recently launched its Enabling Technologies division, which will leverage the company&#39;s core mission of addressing unmet pediatric needs in orthopedics.</p>
<p>The advancement with the latest launch positions OrthoPediatrics at the forefront of the pediatric digital health and enabling technologies sectors.</p>
<p>Following the announcement, shares of OrthoPediatrics rose 2.15% to $32.38 on Friday. The company continues to gain a high level of synergies from its various latest developments within the pediatric digital health space. Accordingly, we expect market sentiment to continue to remain positive around this announcement.</p>
<h2>More on OrthoPediatrics&#39; Enabling Technologies Division</h2>
<p>Led by industry veteran Kevin Unger, this new division is set to differentiate OrthoPediatrics&#39; core business, generate sustainable revenue growth, and gain access to new markets and specialties beyond orthopedics.</p>
<p>The company has made significant strides in the field through its distribution of the 7D Flash Navigation System. Additionally, it collaborated with 3D Side, S.A. for patient-specific cutting guides. These innovations have laid a strong foundation for the Enabling Technologies division.</p>
<h2>OrthoPediatrics&#39; Business Advancements</h2>
<p>Given the success of the above-mentioned developments, KIDS is all set to launch its two groundbreaking technology platforms. First, Playbook is a cutting-edge surgical workflow and outcome optimization platform. It is designed to enhance surgical planning, collaboration and intraoperative workflow. Playbook is aimed at revolutionizing how surgeries are planned and executed, potentially resulting in improved outcomes and more efficient processes.</p>
<p>Second, Robotic-Assistance is for Cochlear Implant Technology.OrthoPediatrics partnered with iotaMotion, Inc. to bring a robotic-assisted insertion system to enhance cochlear implant surgery. This technology offers a slow electrode array insertion that is agnostic to cochlear implant manufacturers, providing greater control and precision for pediatric patients.</p>
<h2>Other Recent Developments by OrthoPediatrics</h2>
<p>In May, the company received the &quot;Breakthrough Device&quot; designation from the&nbsp;Food and Drug Administration&nbsp;for its new eLLi surgical device. eLLi is an implant designed to address severe pathology associated with early onset scoliosis, which can be associated with thoracic insufficiency, a potentially life-threatening condition. This innovative product should be a great addition to the suite of products for pediatric patients with scoliosis.</p>
<p>Earlier this year, OrthoPediatrics launched a new RESPONSE Rib and Pelvic Fixation system to treat children with EOS. The system represents&nbsp;OrthoPediatrics&#39;&nbsp;first solution to treat patients at risk of thoracic insufficiency syndrome. The new addition to the RESPONSE portfolio includes implants and instruments for rib and pelvic fixation, and associated devices to connect the fixation points.&nbsp;</p>
<h2>Industry Prospects Favor OrthoPediatrics</h2>
<p>Per a Grand View Research report, the global pediatric orthopedic devices market was valued at $3.83 billion in 2023 and is projected to witness a CAGR of 11.0% from 2024 to 2030.</p>
<p>Primary factors behind the projected market surge include growing awareness of orthopedic conditions in children and the rise in congenital &amp; developmental disorders. Furthermore, innovations such as adjustable &amp; customizable devices and improved materials for better functionality &amp; safety are fueling market growth.</p>
<p>Henceforth, OrthoPediatrics&#39; latest announcement is well-timed.</p>
<h2>KIDS&#39; Price Performance</h2>
<p>Year to date, shares of KIDS have risen 0.7% compared with the industry&#39;s 9.3% growth.</p>
<h2>KIDS&#39; Zacks Rank and Other Key Picks</h2>
<p>KIDS currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2.</p>
<p>Intuitive Surgical&#39;s shares have surged 64.3% in the past year. Estimates for the company&#39;s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 156.9% in the past year compared with the industry&#39;s 17.5% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 57.2% compared with the industry&#39;s 19.5% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2336322/kids-stock-gains-from-its-new-enabling-technologies-division-launch?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336322">To read this article on Zacks.com click here.</a></p>


ISRG

KIDS Stock Gains From Its New Enabling Technologies Division Launch

<p>Truist Securities  analyst Richard Newitter   reiterates OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Hold and raises the price target from $30 to $34.</p>


Price Target

Reiteration

Truist Securities Reiterates Hold on OrthoPediatrics, Raises Price Target to $34

<p>JMP Securities  analyst David Turkaly   reiterates OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Market Outperform and maintains $50 price target.</p>


JMP Securities Reiterates Market Outperform on OrthoPediatrics, Maintains $50 Price Target

<p>4 analysts have shared their evaluations of OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $37.25, a high estimate of $42.00, and a low estimate of $30.00. A 5.1% drop is evident in the current average compared to the previous average price target of $39.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726228880_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive OrthoPediatrics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$35.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to OrthoPediatrics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for OrthoPediatrics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of OrthoPediatrics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on OrthoPediatrics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know OrthoPediatrics Better</h2>
<p>OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.</p>
<h3>Unraveling the Financial Story of OrthoPediatrics</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> OrthoPediatrics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>33.48%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> OrthoPediatrics's net margin excels beyond industry benchmarks, reaching <strong>-11.42%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> OrthoPediatrics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-1.63%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> OrthoPediatrics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-1.39%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> OrthoPediatrics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Latest Analyst Ratings For OrthoPediatrics

<p>Needham  analyst Mike Matson   reiterates OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Buy and maintains $42 price target.</p>


Needham Reiterates Buy on OrthoPediatrics, Maintains $42 Price Target

<p>The Enabling Technologies division will leverage the company&#39;s core mission of addressing unmet pediatric needs in orthopedics and apply this focus to new areas within digital health and advanced technology.</p>
<p>Led by industry veteran, Kevin Unger, this new division is set to differentiate OrthoPediatrics&#39; core business, generate sustainable revenue growth, and access new markets and specialties beyond orthopedics.<br />
&nbsp;</p>


OrthoPediatrics Reports Launch Of Its Enabling Technologies Division

<p>Truist Securities  analyst Richard Newitter   reiterates OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Hold and lowers the price target from $35 to $30.</p>


Truist Securities Reiterates Hold on OrthoPediatrics, Lowers Price Target to $30

OrthoPediatrics Reaffirms 2024 Revenue Guidance Of $200M-$203M

<p>OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.27) by 14.81 percent.  The company reported quarterly sales of $52.802 million which beat the analyst consensus estimate of $52.495 million by 0.59 percent.  This is a 33.48 percent increase over sales of $39.559 million the same period last year.</p>


OrthoPediatrics Q2 2024 Adj. EPS $(0.23) Beats $(0.27) Estimate, Sales $52.802M Beat $52.495M Estimate

<p>Truist Securities  analyst Samuel Brodovsky   maintains OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Hold and lowers the price target from $38 to $35.</p>


Truist Securities Maintains Hold on OrthoPediatrics, Lowers Price Target to $35

<p>Truist Securities  analyst Samuel Brodovsky   maintains OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Hold and raises the price target from $35 to $38.</p>


Truist Securities Maintains Hold on OrthoPediatrics, Raises Price Target to $38

<p>7 analysts have expressed a variety of opinions on OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for OrthoPediatrics, presenting an average target of $40.29, a high estimate of $50.00, and a low estimate of $32.00. Witnessing a positive shift, the current average has risen by 20.88% from the previous average price target of $33.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715108412_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive OrthoPediatrics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$32.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OrthoPediatrics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of OrthoPediatrics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of OrthoPediatrics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on OrthoPediatrics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering OrthoPediatrics: A Closer Look</h2>
<p>OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.</p>
<h3>OrthoPediatrics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining OrthoPediatrics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>21.36%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> OrthoPediatrics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-17.79%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> OrthoPediatrics's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-1.78%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.54%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, OrthoPediatrics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For OrthoPediatrics

<p>Needham  analyst Mike Matson   maintains OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) with a Buy and raises the price target from $37 to $42.</p>


Needham Maintains Buy on OrthoPediatrics, Raises Price Target to $42

OrthoPediatrics Sees FY24 Revenue $200M-$203M Vs $198.125M Estimate

<p>OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.40) by 25 percent. This is a 3.45 percent decrease over losses of $(0.29) per share from the same period last year.  The company reported quarterly sales of $44.685 million which beat the analyst consensus estimate of $41.775 million by 6.97 percent.  This is a 41.46 percent increase over sales of $31.588 million the same period last year.</p>


OrthoPediatrics Q1 2024 Adj EPS $(0.30) Beats $(0.40) Estimate, Sales $44.685M Beat $41.775M Estimate

<p><strong>OrthoPediatrics Corp.</strong> ("OrthoPediatrics") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received the "Breakthrough Device" Designation from the Food and Drug Administration ("FDA") for its new eLLi surgical device, an implant designed to address severe pathology associated with Early Onset Scoliosis (EOS), which can be associated with thoracic insufficiency, a potentially life-threatening condition.&nbsp;eLLi aims to provide a non-invasive means of extending the growing rods that provides increased force, enhanced mechanical reliability, and superior distraction precision, while also addressing safety concerns associated with current technology. eLLi will allow surgeons a new alternative to address deformity of the growing spine with an advanced technology that will complement our efforts to build a platform of EOS technologies.&nbsp; We are proud to have an expert design team comprised of surgeons who have dedicated their careers to treating these unique patients.&nbsp;<br /><br />&nbsp;</p>
<p>According to the FDA, the Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The Breakthrough Program is intended to help patients have more timely access to medical devices by expediting their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency's mission to protect and promote public health.</p>
<p>David Bailey, OrthoPediatrics' President &amp; CEO, commented, "Receiving the Breakthrough Device designation from the FDA is a great achievement for our team. This innovative product will be a great addition to our suite of products for pediatric patients with Scoliosis and represents our commitment to continuous innovation and advancing healthcare for children all over the world. I'm incredibly proud of my colleagues for all the work they are doing to deliver novel technologies to our surgeon customers and the KIDS they treat!"&nbsp;&nbsp;&nbsp;</p>


OrthoPediatrics Corp. Receives "Breakthrough Device" Designation From FDA For eLLi Growing Rod System For Pediatric Patients With Scoliosis

OrthoPediatrics Corp. (KIDS) Q2 2024 Earnings Call Transcript

An update from OrthoPediatrics (KIDS) is now available. OrthoPediatrics Corp.'s executive team is gearing up for a series of presentations to key f...

OrthoPediatrics Enhances Investor Relations with Strategic Presentations

Piper Sandler Reaffirms Their Buy Rating on OrthoPediatrics (KIDS)

OrthoPediatrics ( ($KIDS) ) just unveiled an update. OrthoPediatrics Corp. is engaging the investment community with a series of presentations, uti...

OrthoPediatrics Showcases Growth and Outlook in Investor Presentations

OrthoPediatrics (KIDS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Turkaly from J...

Buy Rating Reaffirmed for OrthoPediatrics on Robust Growth Strategy and Strong Financials

Needham analyst Michael Matson has reiterated their bullish stance on KIDS stock, giving a Buy rating today. Michael Matson has given his Buy ratin...

Buy Rating Affirmed: OrthoPediatrics' Strategic Growth and Financial Upside

Piper Sandler Sticks to Their Buy Rating for OrthoPediatrics (KIDS)

In a report released today, Richard Newitter from Truist Financial initiated coverage with a Hold rating on OrthoPediatrics (KIDS – Research Report...

OrthoPediatrics (KIDS) Initiated with a Hold at Truist Financial

Analyst Ryan Zimmerman of BTIG maintained a Buy rating on OrthoPediatrics (KIDS – Research Report), retaining the price target of $44.00. Ryan Zimm...

Buy Rating Affirmed for OrthoPediatrics: Strong Growth and Strategic Expansion Underpin Positive Outlook

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on OrthoPediatrics (KIDS – Research Report) today and set a price target of $40.00. The c...

Comments

OrthoPediatrics

Actualités

Dernières nouvelles pour OrthoPediatrics (NASDAQ:KIDS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL